These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38862583)

  • 1. Author Correction: Degeneration of muscle spindles in a murine model of Pompe disease.
    Watkins B; Schultheiß J; Rafuna A; Hintze S; Meinke P; Schoser B; Kröger S
    Sci Rep; 2024 Jun; 14(1):13394. PubMed ID: 38862583
    [No Abstract]   [Full Text] [Related]  

  • 2. Degeneration of muscle spindles in a murine model of Pompe disease.
    Watkins B; Schultheiß J; Rafuna A; Hintze S; Meinke P; Schoser B; Kröger S
    Sci Rep; 2023 Apr; 13(1):6555. PubMed ID: 37085544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.
    Liang Q; Vlaar EC; Pijnenburg JM; Rijkers E; Demmers JAA; Vulto AG; van der Ploeg AT; van Til NP; Pijnappel WWMP
    J Proteomics; 2024 Jan; 291():105037. PubMed ID: 38288553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
    Ziegler RJ; Bercury SD; Fidler J; Zhao MA; Foley J; Taksir TV; Ryan S; Hodges BL; Scheule RK; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2008 Jun; 19(6):609-21. PubMed ID: 18500944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease.
    Stok M; de Boer H; Huston MW; Jacobs EH; Roovers O; Visser TP; Jahr H; Duncker DJ; van Deel ED; Reuser AJJ; van Til NP; Wagemaker G
    Mol Ther Methods Clin Dev; 2020 Jun; 17():1014-1025. PubMed ID: 32462050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells.
    Kawagoe S; Higuchi T; Meng XL; Shimada Y; Shimizu H; Hirayama R; Fukuda T; Chang H; Nakahata T; Fukada S; Ida H; Kobayashi H; Ohashi T; Eto Y
    Mol Genet Metab; 2011; 104(1-2):123-8. PubMed ID: 21703893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired muscle spindle function in murine models of muscular dystrophy.
    Gerwin L; Rossmanith S; Haupt C; Schultheiß J; Brinkmeier H; Bittner RE; Kröger S
    J Physiol; 2020 Apr; 598(8):1591-1609. PubMed ID: 32003874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle spindles of the multifidus muscle undergo structural change after intervertebral disc degeneration.
    James G; Stecco C; Blomster L; Hall L; Schmid AB; Shu CC; Little CB; Melrose J; Hodges PW
    Eur Spine J; 2022 Jul; 31(7):1879-1888. PubMed ID: 35618974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
    Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS
    Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
    Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH
    Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetization Transfer Ratio in Lower Limbs of Late Onset Pompe Patients Correlates With Intramuscular Fat Fraction and Muscle Function Tests.
    Nuñez-Peralta C; Montesinos P; Alonso-Jiménez A; Alonso-Pérez J; Reyes-Leiva D; Sánchez-González J; Llauger-Roselló J; Segovia S; Belmonte I; Pedrosa I; Martínez-Noguera A; Matellini-Mosca B; Walter G; Díaz-Manera J
    Front Neurol; 2021; 12():634766. PubMed ID: 33796064
    [No Abstract]   [Full Text] [Related]  

  • 12. Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease.
    Piras G; Montiel-Equihua C; Chan YA; Wantuch S; Stuckey D; Burke D; Prunty H; Phadke R; Chambers D; Partida-Gaytan A; Leon-Rico D; Panchal N; Whitmore K; Calero M; Benedetti S; Santilli G; Thrasher AJ; Gaspar HB
    Mol Ther Methods Clin Dev; 2020 Sep; 18():558-570. PubMed ID: 32775491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease.
    Tarallo A; Damiano C; Strollo S; Minopoli N; Indrieri A; Polishchuk E; Zappa F; Nusco E; Fecarotta S; Porto C; Coletta M; Iacono R; Moracci M; Polishchuk R; Medina DL; Imbimbo P; Monti DM; De Matteis MA; Parenti G
    EMBO Mol Med; 2021 Nov; 13(11):e14434. PubMed ID: 34606154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies.
    Aguilar-González A; González-Correa JE; Barriocanal-Casado E; Ramos-Hernández I; Lerma-Juárez MA; Greco S; Rodríguez-Sevilla JJ; Molina-Estévez FJ; Montalvo-Romeral V; Ronzitti G; Sánchez-Martín RM; Martín F; Muñoz P
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blepharoptosis in infantile onset Pompe disease: Histological findings and surgical outcomes.
    Chen YH; Huang PW; Liu YJ; Tsai YJ
    Mol Genet Metab Rep; 2023 Jun; 35():100969. PubMed ID: 36967722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
    Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
    J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.
    Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH
    Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.